Quris Technologies

The company's core offering is its Bio-AI Clinical Prediction Platform, which forecasts the clinical safety and efficacy of new drug candidates before they enter human trials. This addresses a major pain point in the pharmaceutical industry, where a high percentage of drugs fail in clinical trials, leading to significant financial losses. The platform integrates several technologies: miniaturized "Patients-on-a-Chip," next-generation nano-sensors, and machine learning algorithms. It tests thousands of drug compounds on these chips, which contain miniaturized human organs grown from stem cells, reflecting a broad genomic diversity through a partnership with the New York Stem Cell Foundation (NYSCF). The data generated from these automated experiments continuously trains the AI models to improve their predictive accuracy, a process protected by 18 granted and pending patents.

Quris serves pharmaceutical and biotechnology firms, providing services to improve their drug candidate selection. A notable collaboration includes a multi-million dollar agreement with Merck KGaA to assess the platform's ability to identify liver toxicity risks. The business model has three pillars: offering prediction services to pharma companies, developing its own pipeline of drugs, and exploring personalized drug safety applications. The company is initially focusing on rare genetic diseases, such as Fragile X syndrome, which are difficult to model using traditional animal testing. To date, Quris has secured $37 million in seed funding from investors including SoftBank Vision Fund 2, GlenRock Capital, iAngels, and Welltech Ventures.